Aditi Shah
Analyst/Associate at Analysis Group
Key Impact
She appears on multiple real-world evidence and health economics papers on ketamine/esketamine for treatment-resistant depression and suicidal ideation, contributing to the evidence base around novel psychiatric treatments.
Background & Research
Aditi Shah is a researcher at Analysis Group whose publications focus on real-world outcomes, healthcare utilization, costs, and access related to esketamine nasal spray and other treatments for treatment-resistant depression. She is listed as an author on multiple papers in the psychiatric and pharmacoeconomic literature, including studies of ketamine/esketamine in depression and suicidality. Based on the available evidence, she appears to be an industry-affiliated health economics/real-world evidence author rather than a clinical psychiatrist.
Collaboration Network
7 collaborators· click a node to visit their profile
Full network →